title: Mature dendritic cells differentiated in the presence of interferon-beta and interleukin-3 prime functional antigen-specific CD8 T cells.
abstract: Dendritic cell (DC)-based immunization represents a promising approach for the immunotherapy of cancer. The optimal conditions required to prepare DCs remain to be defined. Monocytes incubated in the presence of interferon (IFN)-beta and interleukin (IL)-3 give rise to a distinct type of DCs (IFN-beta/IL-3 DCs) that are particularly efficient at eliciting IFN-gamma and IL-5 production by allogeneic helper T cells. We assessed the capacity of this new type of DCs to prime antigen-specific naive CD8(+) T cells and compared them to the conventional DCs differentiated in the presence of granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-4 (GM-CSF/IL-4 DCs). We demonstrate that IFN-beta/IL-3 DCs matured by TLR3 or CD40 ligation efficiently prime Melan-A(26-35)-specific CD8(+) T cells in vitro, at a similar level as GM-CSF/IL-4 DCs. Activated antigen-specific CD8(+) T cells produced IFN-gamma and displayed potent cytotoxic activity against peptide-pulsed target cells. Expansion of CD8(+) T cell numbers was generally higher following priming with CD40-L than with polyinosinic-polycytidylic acid (poly I:C) matured DCs. Cytolytic activity was induced by both maturing agents. These data indicate that IFN-beta/IL-3 DCs represent a promising cell population for the immunotherapy of cancer.
authors.affiliation: Cancer Research Tumour Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK.
authors.forename: J
authors.initials: J
authors.lastname: Renneson
authors.forename: M
authors.initials: M
authors.lastname: Salio
authors.forename: N
authors.initials: N
authors.lastname: Mazouz
authors.forename: M
authors.initials: M
authors.lastname: Goldman
authors.forename: A
authors.initials: A
authors.lastname: Marchant
authors.forename: V
authors.initials: V
authors.lastname: Cerundolo
mesh_terms: D023201:CD40 Ligand / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines; D002454:Cell Differentiation; D045744:Cell Line, Tumor; D003713:Dendritic Cells / Q000276:immunology*; D005434:Flow Cytometry; D006801:Humans; D016899:Interferon-beta / Q000276:immunology*; D007371:Interferon-gamma / Q000276:immunology; D007377:Interleukin-3 / Q000276:immunology*; D015848:Interleukin-5 / Q000276:immunology; D008213:Lymphocyte Activation; D008223:Lymphoma / Q000276:immunology / Q000628:therapy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
chemical_list: D019496:Cancer Vaccines; D007377:Interleukin-3; D015848:Interleukin-5; D023201:CD40 Ligand; D016899:Interferon-beta; D007371:Interferon-gamma
references.citation: Cancer Res. 2003 May 1;63(9):2127-33
references.pmid: 12727829
references.citation: Clin Cancer Res. 2004 May 1;10(9):2944-53
references.pmid: 15131029
references.citation: J Immunol. 2011 Jul 1;187(1):7-9
references.pmid: 21690331
references.citation: J Exp Med. 1999 Dec 6;190(11):1669-78
references.pmid: 10587357
references.citation: J Immunol. 2004 May 1;172(9):5363-70
references.pmid: 15100276
references.citation: J Immunol. 1997 Sep 1;159(5):2366-74
references.pmid: 9278327
references.citation: Eur J Immunol. 2003 Apr;33(4):1052-62
references.pmid: 12672071
references.citation: J Surg Res. 2004 Jan;116(1):24-31
references.pmid: 14732346
references.citation: Nat Med. 2004 May;10(5):475-80
references.pmid: 15122249
references.citation: Nat Immunol. 2004 Jan;5(1):7-10
references.pmid: 14699398
references.citation: J Clin Invest. 2002 Aug;110(3):289-94
references.pmid: 12163445
references.citation: Stem Cells. 2003;21(3):357-62
references.pmid: 12743330
references.citation: Blood. 2002 Feb 1;99(3):993-8
references.pmid: 11807004
references.citation: J Immunol. 2003 May 15;170(10):5195-202
references.pmid: 12734367
references.citation: J Exp Med. 2004 Feb 16;199(4):567-79
references.pmid: 14970182
references.citation: J Exp Med. 1994 Apr 1;179(4):1109-18
references.pmid: 8145033
references.citation: J Clin Invest. 2004 Jun;113(11):1515-25
references.pmid: 15173875
references.citation: J Immunol. 2003 Oct 1;171(7):3385-93
references.pmid: 14500632
references.citation: J Exp Med. 2002 Feb 4;195(3):335-41
references.pmid: 11828008
references.citation: J Immunol. 2001 Aug 1;167(3):1188-97
references.pmid: 11466333
references.citation: Nat Immunol. 2003 Oct;4(10):1009-15
references.pmid: 14502286
references.citation: Annu Rev Immunol. 2000;18:767-811
references.pmid: 10837075